Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

57.50 +0.57 (+1.00%)
Official Closing Price Updated: 4:10 PM EDT, Oct 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Why Is Scholar Rock Stock Trading Lower On Monday?
Scholar Rock stock falls as FDA issues Form 483 to Catalent; company to meet FDA, while apitegromab shows lean mass preservation in trial. 
Via Benzinga
Why Are Regeneron And Scholar Rock Shares Falling On Monday?
Regeneron and Scholar Rock’s submissions have been delayed or denied following an FDA inspection at the third-party fill-finish facility Catalent Indiana, owned by Novo Nordisk. 
Via Stocktwits
Down 44%, Should You Buy the Dip on Viking Therapeutics?
The company is readying to take on pharma giants Novo Nordisk and Eli Lilly. 
Via The Motley Fool
The Smartest Growth Stock to Buy With $100 Right Now
This beaten-down drugmaker is well positioned to turn things around. 
Via The Motley Fool
Drug Stocks Just Had Their Best Week in 2 Decades. Should You Invest?
Now may be the time to invest in drug companies, as they just slipped the tariff noose. 
Via The Motley Fool
Topics ETFs Government World Trade
Novo Nordisk Reportedly Slashes Workforce At Its US Wegovy Manufacturing Plant
Via Stocktwits
Novo Nordisk Retail Traders Stay Bullish Despite Brutal 2025 — Analysts Flag A Key Catalyst That Can Turn Things Around
Via Stocktwits
3 Top Healthcare Stocks to Buy in October
Healthcare stocks haven't been very popular this year. It could be a great time to buy some of the industry's leaders. 
Via The Motley Fool
Topics Economy Government Intellectual Property
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO): A Prime Example of Affordable Growth
Novo Nordisk exemplifies affordable growth, combining strong revenue and earnings expansion with a reasonable valuation and top-tier profitability. 
Via Chartmill
Should You Buy Novo Nordisk Right Now?
The fallen pharma giant could make a big comeback in 2026. 
Via The Motley Fool
Bill Gates And PAHO Push To Make Weight-Loss Drugs Accessible In Low-Income Nations
Bill Gates and PAHO are working to make weight-loss drugs like Wegovy and Mounjaro more affordable for low-income countries. 
Via Benzinga
Delta Air Lines, Tilray Brands, UiPath, Akero Therapeutics, Apogee Therapeutics: Stocks Making The Biggest Moves Today
Via Stocktwits
Eli Lilly Completes Phase 1 Study for Bimagrumab and Tirzepatide Amidst Strategic Pipeline Revisions
Eli Lilly and Company (NYSE: LLY) has announced the completion of its Phase 1 bioavailability study for the combination of Bimagrumab and Tirzepatide on October 8, 2025, a foundational step in... 
Via MarketMinute
Eastover Opens a Brand New $3.3 Million Novo Nordisk Position
Via The Motley Fool
Topics Regulatory Compliance
Novo Nordisk To Acquire Liver Disease Focused Akero Therapeutics For Around $5 Billion
Novo Nordisk to buy Akero Therapeutics for up to $5.2 billion, adding EFX, a late-stage MASH treatment candidate, to its metabolic disease portfolio. 
Via Benzinga
Novo Nordisk Bulks Up Its Obesity-Tied Portfolio With $4.7 Billion Buyout
The deal follows Roche's plan to buy 89bio, another MASH-focused biotech company. 
Via Investor's Business Daily
Dow Futures Inch Up As Wall Street Awaits Jerome Powell’s Speech: TSLA, NVO, DAL, PEP Among Stocks To Watch
Via Stocktwits
Topics Economy Stocks
What’s Driving The Super Rally In Akero Shares On Thursday Morning?
Novo Nordisk is set to acquire the firm, and Akero’s shareholders will receive $54 per share in cash at closing in addition to a contingent value right. 
Via Stocktwits
Carolina Wealth Makes a Big $6 Million Bet on Novo Nordisk (NYSE: NVO)
Via The Motley Fool
Wegovy, Ozempic Maker Novo Nordisk Cuts Staff At Key US Production Sites
Novo Nordisk has cut dozens of jobs at its Clayton, North Carolina site, part of a global restructuring as it faces slowing weight-loss drug sales. 
Via Benzinga
Where Will LLY Be in 5 Years?
After nearly two years of sideways price action, Eli Lilly stock could soar to new highs between now and 2030. 
Via The Motley Fool
Topics World Trade
Skye Bioscience's Investigational Drug Disappoints As Monotherapy For Weight Loss
Skye Bioscience'a trial showed nimacimab alone missed goals, while a combo with Novo Nordisk's drug delivered stronger weight loss results. 
Via Benzinga
2 Beaten-Down Stocks Primed for a Comeback
The market is sleeping on these stocks, but you don't have to. 
Via The Motley Fool
Anthropic’s Claude AI: Seamless Integration into Everyday Life
Anthropic, a leading artificial intelligence research company, is making significant strides in embedding its powerful Claude AI into the fabric of daily applications and enterprise workflows. With a... 
Via TokenRing AI
Topics Artificial Intelligence
Novo Nordisk (NVO) Soars as HSBC Upgrades to "Buy," Citing Strategic Focus and Pipeline Strength
Copenhagen, Denmark – October 2, 2025 – Shares of Danish pharmaceutical giant Novo Nordisk (NYSE: NVO) experienced a significant surge yesterday, October 1, 2025, following a pivotal upgrade from HSBC.... 
Via MarketMinute
Topics Economy
This Nike Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
 
Via Benzinga
Novo Nordisk (NYSE:NVO) Presents a Compelling Case for Value Investors
Novo Nordisk (NVO) presents a strong value investment case with an attractive valuation, high profitability, and solid financial health. 
Via Chartmill
Why Shares in Novo Nordisk Bumped Higher Today
Pfizer's deal with the Trump administration raised hopes that the European company wouldn't be subject to 100% tariffs on certain imported drugs. 
Via The Motley Fool
Topics Government World Trade
Q3 2025 Market Marvels: S&P 500's Standout Performers and Their Catalysts
As the third quarter of 2025 draws to a close, the financial markets are abuzz with the exceptional performances of several S&P 500 companies. While official data is still being compiled, preliminary... 
Via MarketMinute
Topics Artificial Intelligence Data Breach Earnings
Pfizer Plummets as Key Obesity Drug Candidate Faces Major Setback, Shaking Investor Confidence
New York, NY – September 30, 2025 – Shares of pharmaceutical giant Pfizer (NYSE: PFE) experienced a dramatic decline today, making it one of the market's bottom performers, following an unexpected and... 
Via MarketMinute
Topics Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.